Professor Steven le Gouill from the Medical University of Nantes in France believes that there are still many uncertainties related to the optimal management of mantle cell lymphoma. In this podcast, he describes his treatment approach in frontline therapy and relapsed refractory disease, while pointing out aspects of ongoing debate.
Part 2 of the podcast discusses patients with relapsed refractory MCL.
This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.
PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au).